{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273228","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.338502+00:00","generated_at":"2026-05-16T22:30:34.181606+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Olema Q3 net loss $42.2M; cash $329M; initiates OPERA-02 Phase 3; Pfizer deal","bullets":["Net loss $42.2M for Q3 2025 vs $34.6M Q3 2024; cash, equivalents and securities $329.0M.","Initiated OPERA-02 Phase 3 trial of palazestrant + ribociclib in frontline ER+/HER2- MBC.","Clinical trial agreement with Pfizer to evaluate palazestrant + atirmociclib in Phase 1b/2.","Phase 1/2 of OP-3136 (KAT6 inhibitor) expanded into combos; initial results expected mid-2026.","Top-line data from OPERA-01 monotherapy Phase 3 expected in second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273228","json":"https://secwatch.observer/filing/0001193125-25-273228.json","markdown":"https://secwatch.observer/filing/0001193125-25-273228.md","text":"https://secwatch.observer/filing/0001193125-25-273228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/0001193125-25-273228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/olma-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:30:34.181606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}